Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free VRPX Stock Alerts

Virpax Pharmaceuticals (VRPX) Competitors

Virpax Pharmaceuticals logo
Compare

VRPX vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy Virpax Pharmaceuticals stock or one of its competitors? Virpax Pharmaceuticals's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Virpax Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Virpax Pharmaceuticals. Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
60 Degrees Pharmaceuticals Neutral

60 Degrees Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
60 Degrees Pharmaceuticals N/A N/A N/A

60 Degrees Pharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

60 Degrees Pharmaceuticals beats Virpax Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, Biofrontera had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Virpax Pharmaceuticals. Biofrontera's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Biofrontera Neutral
Virpax Pharmaceuticals Neutral

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biofrontera's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

Biofrontera has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Summary

Biofrontera beats Virpax Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Cingulate?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Cingulate's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Cingulate N/A N/A N/A

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Cingulate Neutral

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
CingulateN/AN/AN/AN/AN/A

Summary

Virpax Pharmaceuticals and Cingulate tied by winning 2 of the 4 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Virpax Pharmaceuticals has lower revenue, but higher earnings than Clever Leaves. Clever Leaves is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Clever Leaves has a beta of 3853.65, indicating that its share price is 385,265% more volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.55, indicating that its share price is 1,755% less volatile than the broader market.

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Virpax Pharmaceuticals Neutral

Clever Leaves' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

Summary

Clever Leaves beats Virpax Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Comera Life Sciences?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Comera Life Sciences Neutral

Comera Life Sciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Comera Life Sciences N/A N/A N/A

Comera Life Sciences has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Comera Life Sciences beats Virpax Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

Get Virpax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRPX vs. The Competition

Export
MetricVirpax PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$14K$12.48B$7.26B$13.14B
Dividend YieldN/A2.63%2.57%12.30%
P/E Ratio0.00797.25275.7925.40
Price / SalesN/A950.97695.58114.47
Price / CashN/A88.4477.4251.66
Price / BookN/A10.5310.466.33
Net Income-$15.19M$2.82B$3.49B$358.33M

Virpax Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRPX
Virpax Pharmaceuticals
N/AN/AN/A-9.0%$14KN/AN/A7
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
+1.7%		N/A-22.0%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.02
-0.5%		N/A-80.7%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
+8.2%		N/A-87.9%$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/A-50.0%$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRPX) was last updated on 9/19/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel